About Acorn Campus Taiwan
Acorn Campus Taiwan is a venture capital firm located in Santa Clara, United States. As of Jan 2022, Acorn Campus Taiwan has invested in 25 companies. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to Enterprise Applications and High Tech. Most recently it participated in the $***** Series A round of URO-1 Overall, Acorn Campus Taiwan portfolio has seen 2 IPOs and 2 acquisitions, namely RenovoRx, Endosee and HP lighting. A lot of funds co-invest with Acorn Campus Taiwan, with names like Boston Scientific sharing a substantial percentage of its portfolio. Acorn Campus Taiwan has team of 3 people including 2 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 1 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Acorn Campus Taiwan's List of Top Investments
Acorn Campus Taiwan has a portfolio of 25 companies. Their most notable investments are in URO-1 and Rasilient.Their portfolio spans across United States, Taiwan and Israel. They have invested in Life Sciences, Enterprise Applications, High Tech and 11 other sectors, across stages such as Series A, Series B and 1 more. Here is the list of top investments by Acorn Campus Taiwan:_1570590286794.png?format=webp&height=120&width=120){kind=logo}
Materna Medical provides a device for women’s pelvic health. It develops devices Milli, a vaginal and pelvic floor dilator, and Materna Prep, to reduce maternal childbirth-related injuries, like perineal lacerations, during vaginal delivery.
Key facts about Materna Medical
- Founded Year: 2010
- Location: Mountain View (United States)
- Stage: Series B
- Total Funding till date: $62.7M
- Employee Count: 34 as on Sep 30, 2026
- Investors: North Bay Angels, InnovaHealth Partners and 17 Others
- Latest Funding Round: Series B, Jul 01, 2026, $*****
- Highlight: Editors' Pick
Biopharmaceutical firm pioneering T-cell therapies for solid tumors and malignancies. The company is dedicated to developing transformative technology platforms to access cancer-specific targets and harness the evolutionary power of T cells. They focus on creating potential treatment options for patients by cultivating a deeper understanding of each type of cancer and leveraging cutting-edge technology platforms. The firm utilizes proprietary platforms for high-throughput screening to develop cancer-specific antibodies and harness the evolutionary power of T cells. Their pipeline highlights the potential to transform cancer treatment. They welcome partners and collaborators to help develop and commercialize novel and complementary technologies to tackle the challenges with solid tumors. The company's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.
Key facts about Eureka Therapeutics
- Founded Year: 2006
- Location: Emeryville (United States)
- Stage: Series E
- Total Funding till date: $176M
- Employee Count: 47 as on Sep 30, 2026
- Investors: Acorn Pacific Ventures, Majuven and 10 Others
- Latest Funding Round: Grant (prize money), Jun 06, 2023, $*****
- Highlight: Editors' Pick
3. RenovoRx
Developer of endovascular catheters for targeted delivery of IV fluids to peripheral organs. It develops endovascular catheters for the visceral and peripheral vascular systems. The RenovoRx device can be used to deliver both therapeutic(such as drugs)and diagnostic fluids(such as contrast agents) to the target organ through veins. The device allows for isolated vessel perfusion i.e. a balloon is inflated within the blood vessels to block blood flow to other organs to maximize the amount of blood flow(and IV fluids reaching the target organ.
Key facts about RenovoRx
- Founded Year: 2009
- Location: Los Altos (United States)
- Stage: Public
- Total Funding till date: $10.9M
- Employee Count: 31 as on Sep 30, 2026
- Investors: Portfolia, b2venture and 10 Others
- Latest Funding Round: Post IPO, Mar 20, 2026, $*****
- Highlight: Public
4. Embolx
Innovating arterial embolization with advanced microcatheter technology for targeted therapies. This medical device company focuses on developing and commercializing microcatheters designed for arterial embolization procedures. Their technology aims to improve the treatment of conditions like cancerous tumors, benign prostatic hyperplasia, and uterine fibroids. The core product line includes balloon occlusion microcatheters that offer precise embolic delivery and target filling by controlling pressure to direct blood flow, protecting surrounding tissues. They are dedicated to driving innovation in the field of arterial embolization, offering resources like clinical evidence, cases, publications, webinars, and white papers to support healthcare professionals. The company is committed to advancing medical technology and improving patient outcomes through targeted embolization solutions.
Key facts about Embolx
- Founded Year: 2013
- Location: Sunnyvale (United States)
- Stage: Seed
- Total Funding till date: $500K
- Employee Count: 21 as on Aug 31, 2026
- Investors: Sood Ventures, VI Ventures and 4 Others
- Latest Funding Round: Grant (prize money), Sep 25, 2015, $*****
5. H3 Platform
Platform offering storage servers. It offers products such as GPU Accelerator, Composable Rack-scale Solution, and NVMe SSD Pooling. The server can be used as an accelerating solution for machine learning and high-performance computing. The NVMe SSD Pooling can be used as a composable storage solution for computing nodes.
Key facts about H3 Platform
- Founded Year: 2014
- Location: Taipei (Taiwan)
- Stage: Funding Raised
- Employee Count: 13 as on Sep 30, 2026
- Investors: Acorn Pacific Ventures and Acorn Campus Taiwan
Acorn Campus Taiwan's Year-on-Year Investment Trends
Acorn Campus Taiwan has invested in 25 companies over the last 23 years, with an average of 0 new investment annually in the last 10 years. Its most recent first time investment was in URO-1 and most recent follow-on round was in Rasilient.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 0 | 0 | 0 |
2024 | 0 | 0 | 0 |
2023 | 0 | 0 | 0 |
2022 | 1 | 0 | 1 |
2021 | 0 | 0 | 0 |
2020 | 1 | 0 | 1 |
2019 | 0 | 0 | 0 |
2018 | 1 | 0 | 1 |
Acorn Campus Taiwan's Investments by Stage
Acorn Campus Taiwan has made 2 investments in Series A stage with an average round size of $4.5M, 1 investment in Series B stage and 1 investment in Series D stage with an average round size of $7M.Stage of entry | No. of Investments |
|---|---|
Series A | 2 |
Series B | 1 |
Series D | 1 |
Note: We have considered here, only first round of investments
Acorn Campus Taiwan's Investments by Sector
Acorn Campus Taiwan has a diverse portfolio, with companies operating in the Life Sciences, Healthcare and High Tech. Notably, it has invested in 21 Tech companies, 19 Enterprise (B2B) companies, 10 Software companies and at least 10 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 2 |
Healthcare | 1 |
High Tech | 1 |
Note: We have considered here, only first round of investments
Acorn Campus Taiwan's Investments by Geography
Acorn Campus Taiwan has made most investments in United States (4), followed by Taiwan where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 4 |
Taiwan | 1 |
Note: We have considered here, only first round of investments
Acorn Campus Taiwan's recent investments
Acorn Campus Taiwan has not made any investment in 2026 so far.Here are the most recent investments by Acorn Campus Taiwan:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jan 04, 2022 | United States | Series A | 2111 | - | |
Jan 23, 2020 | United States | Series B | 7599 | ||
May 23, 2018 | United States | Series D | 1588 | [+5] | |
Jun 04, 2009 | United States | Series A | 8685 | ||
2003 | United States | Series A | 2902 |
IPOs and Publicly Listed companies in Acorn Campus Taiwan's Portfolio
2 of Acorn Campus Taiwan's portfolio companies have become public. RenovoRx got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Aug 2021 at marketcap of $75.5M and HP lighting got listed on the Taipei Stock Exchange (TT).Here are Acorn Campus Taiwan's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Aug 26, 2021 | May 23, 2018 | Series D | 1860 | |
Dec 15, 2015 | - | - | 8309 |
Acquired companies in Acorn Campus Taiwan's Portfolio
2 companies from Acorn Campus Taiwan's portfolio have been acquired. The most recent acquisition was Ciel Medical Devices in Apr 2017 by Vyaire for $*****.Here are Acorn Campus Taiwan's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Apr 20, 2017 | - | - | 2765 | |
Oct 08, 2014 | - | - | 4909 |
Team profile of Acorn Campus Taiwan
Acorn Campus Taiwan has a team of 3 members including 2 Partners and 1 Principal located in United States. Acorn Campus Taiwan's team does not sit on the board of any company as of now.Here is a list of all team members in Acorn Campus Taiwan:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | San Francisco | - | ||
Partner | Santa Clara | - | - | |
Principal | San Francisco | - | - |
Co-investors of Acorn Campus Taiwan
Over the past 23 years, 14 investors have co-invested in Acorn Campus Taiwan's portfolio companies. This includes only funds.
- Invested before Acorn Campus Taiwan: Golden Seeds, The Angels’ Forum and 3 others have invested in rounds before Acorn Campus Taiwan. There is 1 company where Golden Seeds has invested before Acorn Campus Taiwan and 1 company where The Angels’ Forum has invested before Acorn Campus Taiwan.
- Top Co-investors of Acorn Campus Taiwan: 6 investors entered a company along with Acorn Campus Taiwan. These include investors like Boston Scientific (1 company).
- Invested after Acorn Campus Taiwan: A total of 3 investors have invested in Acorn Campus Taiwan's portfolio after their investments. Top Investors include Taiwania Capital (1 company), Industrial Technology Investment Corporation (1 company) and fidelitas-intl.com (1 company).
Recent News related to Acorn Campus Taiwan
•
URO-1 Achieves Multiple Milestones Toward Commercializing Its Breakthrough Products for Prostate Biopsy & Other ProceduresMedical Device News•Jan 04, 2022•URO-1, Acorn Campus Taiwan
•
The Clinical Safety Innovator, Flat Medical, Secured Series B Financing for Global DevelopmentBusiness Wire•Jan 23, 2020•Flat Medical, Acorn Campus Taiwan, National Development Council
•
RenovoRx Announces $10 Million Financing for Innovative Treatment for Advanced Pancreatic CancerBusiness Wire•May 23, 2018•RenovoRx, Boston Scientific, BtoV, Astia and 4 others
